| |
|
|
|
|
|
|
|||
|
Blood, 15 March 2006, Vol. 107, No. 6, pp. 2531-2535. Prepublished online as a Blood First Edition Paper on November 29, 2005; DOI 10.1182/blood-2005-04-1768.
NEOPLASIA Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletionFrom the Hematology Section, Department of Biomedical Sciences, Azienda Ospedaliero-Universitaria Arcispedale S. Anna; and the Microbiology Section, Department of Experimental and Diagnostic Medicine and Centro Interdipartimentale per la Ricerca sul Cancro; University of Ferrara, Italy.
In multiple myeloma (MM), circulating endothelial cells (CECs) represent a vascular marker of angiogenesis and may reflect tumor mass. In this report, we showed that, in 5 MM patients with 13q14 deletion, CECs carried the same chromosome aberration as the neoplastic plasma cells (11%-32% of CECs with 13q14 deletion). Most of the CECs displayed immunophenotypic features of endothelial progenitor cells as they expressed CD133, a marker gradually lost during endothelial differentiation and absent on mature endothelial cells. To the contrary, in 3 patients with monoclonal gammopathy of undetermined significance and 13q14 deletion, CECs were cytogenetically normal and had a mature immunophenotype. In MM CECs, immunoglobulin genes were clonally rearranged. These findings suggest a possible origin of CECs from a common hemangioblast precursor that can give rise to both plasma cells and endothelial cells and point to a direct contribution of MM-derived CECs to tumor vasculogenesis and possibly to the spreading and progression of the disease. (Blood. 2006;107:2531-2535)
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||